Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A

NASDAQ:KNSA   3:59:50 PM EDT
12.00
-0.18 (-1.48%)
Other Pre-Announcement

Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results And Provides Corporate Update

Published: 08/03/2022 12:13 GMT
Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A (KNSA) - Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update.
Sees FY Revenue $115 Million to $130 Million.
Arcalyst Full-year 2022 Net Revenue Expected to Be $115 - $130 Million.
Kiniksa Pharma Sees Cash,cash Equivalents to Fund Current Operating Plan Into at Least 2025 After Close of Vixarelimab Global License Agreement.
Qtrly Loss per Share $0.29.